Purpose. We evaluated the effects of combined treatment with the antiestrogen agent toremifene (TOR) and local hyperthermia (LHT) on the MCF-7 breast cancer cell line. Methods. BALB/c mice implanted with MCF-7 cells were divided into six treatment groups: a control group, a TOR30 group (given 30 mg/kg/day), a TOR120 group (given 120 mg/kg/day), an LHT group (43.5°C), a TOR30 + LHT group, and a TOR120 + LHT group. The effects of the treatments on tumor cells, estrogen receptor (ER) expression, and cell cycle kinetics were measured after 21 days. We calculated the apoptotic index and vascular density inside the tumors and evaluated the effi cacy of the transmigration of TOR into the tumors. Results. The antitumor effects were signifi cantly greater in both combined therapy groups than in any of the single therapy groups. Estrogen receptor expression was weaker in the combined therapy groups than in the single therapy groups, and there were more G0/G1-phase cells and fewer S-phase cells in both combined therapy groups than in the single therapy groups. The apoptotic index was increased and the tumor vascular density was decreased in the combined therapy groups. Conclusions. We attributed the effects of this combined therapy to the induction of apoptosis, the decrease in vascular density, and the increase and decrease in G0/G1-phase and S-phase cells, respectively, in the tumors.
Introduction
The novel antiestrogen agent toremifene (TOR) is widely used in the treatment of estrogen receptor (ER)-positive breast cancer patients. Tamoxifen (TAM) is thought to exert its antitumor effect by competitive inhibition of the binding of estrogen to the ER, by its antiestrogen actions. 1, 2 However, studies have found that the long-term use of TAM is associated with risks, including the possible development of secondary cancers such as endometrial cancer. 3, 4 This has led to the creation of safer antiestrogens and other endocrine agents, such as pure antiestrogens, luteinizing hormonereleasing hormone (LH-RH) agonists, and aromatase inhibitors. The incidence of secondary endometrial cancer has been reported to be lower with toremifene than with TAM. The risks of stroke, pulmonary embolism, and cataract may also be lower with TOR than with TAM. 5 The fi ndings of several studies conducted to clarify the mechanisms of antiestrogen agents suggest that they induce apoptosis [6] [7] [8] and inhibit angiogenesis in malignant breast tumors. 9, 10 Hyperthermia (HT), which exerts selective antitumor effects because of its specifi city against tumor blood vessels, has been applied clinically, either alone or in combination with chemotherapy or radiation therapy, in the treatment of various malignant tumors, including breast cancer.
The 2007 National Comprehensive Cancer Clinical Practice Guidelines in Oncology include the use of HT with re-irradiation as a treatment option for women with recurrent locoregional advanced breast cancer after failed fi rst-line surgery or radiation therapy. However, the technology of HT is made incomplete by a lack of standardization in regard to the radiation therapy dose and fractions, heating temperature goals, treatment plans, and duration of exposure. It is also diffi cult to monitor the temperature of the target, or thermometry. 11 Thus, the mechanism underlying the effects of HT has also been the focus of many studies. Expression of heat shock protein 70 in the drugsensitive breast cancer cell line MCF-7 and the corresponding multidrug-resistant cell line MCF-7/ADR were signifi cantly enhanced by HT. The cytotoxic activity of immunologic effector cells against both the target cell lines was enhanced by HT. 12 Some studies have also pointed out the possible induction of apoptosis [13] [14] [15] [16] and inhibition of angiogenesis in tumors by this treatment modality. 17 Although combined therapy with an antiestrogen agent and HT has been applied clinically for breast cancer, there are very few reports analyzing the mechanism underlying the effects of combined treatment with an antiestrogen agent and HT. Thus, we evaluated the effects of combined therapy with the novel antiestrogen agent TOR, which can be given in high doses, and local HT (LHT), in nude mice transplanted with MCF-7 breast cancer cells. The antitumor effects and the mechanisms involved were investigated.
Materials and Methods

Animals and Tumor Cell Line
Female BALB/c nu/nu nude mice were purchased from Clea Japan (Tokyo) and reared in isoracks maintained at a consistent room temperature and humidity. The mice weighed about 20 g and were between 7 and 8 weeks old at the time of the experiment. The cell line used was MCF-7, a nude mouse-transplantable human breast cancer cell line. MCF-7 is an ER-positive breast cancer cell line, which was extracted from the cancerous pleural fl uid of a 69-year-old postmenopausal breast cancer patient in 1970 and established in culture by Soule et al. 18 at the Michigan Cancer Foundation. Estradiol dipropionate, 5 mg/kg, and progesterone caproate, 250 mg/kg, 19 were injected into a muscle in the femoral region at the time of transplantation; then, from 2 weeks later, the tumor diameter was measured twice a week using sliding calipers, and the estimated tumor weight (mg) was calculated using the following equation: longest diameter (mm) × shortest diameter (mm) 2 × 0.5. 20 When the estimated tumor weight had reached approximately 100 mg, the mice were divided into six treatment groups. At various times during the treatment, relative mean tumor weight (RW) was calculated by dividing the mean tumor weights at the time by the mean tumor weight at the start of treatment. Tumor growth curves were drawn by plotting the course of changes in the RWs over the passage of time.
The antiestrogen agent used for this study was 2-[4-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-N,Ndimethylethylamine-citrate (toremifene): the drug was provided by Orion Corporation Farmos (Turku, Finland) through Nippon Kayaku (Tokyo, Japan). Toremifene was suspended in physiological saline containing 2.88% polyethylene glycol 4000, 0.129% Tween 80, and 0.173% methyl parahydroxy benzoate. Toremifene was administered at 0.1 ml/20 g mouse body weight in terms of volume, or at an equivalent of 10, 30, 60, 120, or 180 mg/kg/day once a day for 21 consecutive days using an oral probe to determine the appropriate dose of administration.
Local HT was performed using a water bath heated to 43.0°C and 43.5°C, in accordance with the method reported by Srinivasan et al. 21 After anesthetizing the mice with intraperitoneal pentobarbital, 30 mg/kg body weight, the subdermal tumors were soaked for 30 min via a hole of about 1 cm diameter opened in the insulating board fi xed on the water surface. The intratumoral temperature was measured using a digital thermometer (DT-300 by Inter Medical, Nagano, Japan). A 150-μm probe was inserted into the tumors before the start of HT for regular monitoring. The tumors were exposed to LHT three times, on days 0, 9, and 18.
The mice were divided into the following six treatment groups: a control group, a TOR30 group (treated with TOR at 30 mg/kg/day for 21 days), a TOR120 group (treated with TOR at 120 mg/kg/day for 21 days), an LHT group (exposed to LHT using a 43.5°C-water bath), a TOR30 + LHT group, and a TOR120 + LHT group. On day 21, the mice were killed and the tumors were extirpated for the following evaluations.
Measurement of ER Expression
Using specimens freeze-preserved at −70°C, ER expression was measured by the Dextran Coated Charcoal method and then converted to protein concentrations by Scatchard plot analysis to obtain the count of binding sites per fi xed protein mass (B max ; fmol/mg protein).
Analysis of the Cell Cycle Kinetics by Flow Cytometry (FCM)
Approximately 200 mg of frozen tissue was minced and mixed with 0.1% RNase and 0.1% Triton X. The fi ltrate and propidium iodine were mixed in equal volumes to obtain a fi nal concentration of 50 μg/ml. The cell cycle kinetics in each group were analyzed by fl ow cytometry (FACScan, Becton Dickinson, San Jose, CA, USA); that is, the percentages of cells in the S phase (%S) and G phase (%G0/G1) were calculated using the software, Sum of Broaded Rectangles (SOBR).
Histological Study
To examine the incidence of apoptosis and angiogenesis in each group, the extirpated tumors were processed into formalin-fi xed paraffi n embedded blocks. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labeling (TUNEL) staining was conducted to identify apoptosis, 22 and Factor VIII immunohistochemical staining was carried out to evaluate angiogenesis.
TUNEL staining was performed using the Apop Tag Kit (Oncor, Gaithersburg, MD, USA). The frequency of apoptosis was counted in 5000 tumor cells under a 200× visual fi eld magnifi cation of the microscope. The percentage of cells stained brown, or positive cells, was defi ned as the apoptotic index (%).
For immunohistochemical staining using factor VIIIrelated antigen (FVIII RAg), blood vessels were stained using a Dako LSAB (Labeled Streptavidin Biotin) Kit (Dako, Glostrup, Denmark). The density of blood vessels was assessed by counting brown-stained or positive cells under a 200× visual fi eld of the microscope in the noncancerous border area and the cancerous border area of the tumor and calculating the mean value from ten visual fi elds.
Measurement of the Concentrations of TOR and its Metabolites, Tore 1 and Tore 2, in the Tumors
The concentrations of TOR and its metabolites, Tore 1 and Tore 2, in the tumors were measured by highperformance liquid chromatography (HPLC) 23 in cooperation with Nippon Kayaku. The HPLC system used was LC-6A with a rheodyne injector (Shimazu, Tokyo, Japan), the UV detector used was SPD-6A (detection wavelength 237 nm) (Shimazu), and the data processing system used was Integrator 7000AS (System Instruments, Tokyo, Japan).
Statistical Analysis
The antitumor effects of TOR at different doses, local HT, and the combination therapy were evaluated by the ANOVA test. In addition, the effects of combined TOR + LHT were assessed by another method. 24, 25 The combined therapy was judged to be effective when the product of the ratio of the relative mean tumor weight (T/C) of single therapy (T) against the control group (C) and the T/C of another single therapy was greater than the T/C of the combined therapy. Student's t-test was used to evaluate the ER values, apoptotic index, density of the blood vessels, %S, %G0/G1, and the concentrations of TOR and its metabolites, Tore 1 and Tore 2, in the tumors. P values of less than 0.05 were considered to be signifi cant.
Results
Antitumor Effects of TOR at Different Doses
We gave the mice TOR at doses of 10, 30, 60, 120, or 180 mg/kg/day. The results of the dose escalation study revealed signifi cantly better dose-dependent antitumor effects in the treatment groups than in the control group, except in the mice given 10 mg/kg/day (Table 1 and Fig. 1 ).
Antitumor Effect of LHT
Local HT was performed at 43.0°C and 43.5°C. Local HT at 43.0°C showed no antitumor effect, and seemed to aggravate tumor growth compared with that in the control group. On the other hand, LHT at 43.5°C had a signifi cant antitumor effect compared with that in the control group and that in the 43.0°C group (Fig. 2) .
Combined TOR + LHT Therapy
Tumor growth was remarkably more suppressed in both the combined TOR + LHT groups than in the single- T/C, ratio of the estimated tumor weight to that at the starting point in the treated group/that in the control group; TOR, toremifene; LHT, local hyperthermia ; open triangles, 30 mg/kg/day (n = 7); closed circles, 60 mg/kg/day (n = 7); closed squares, 120 mg/kg/day (n = 7); closed triangles, 180 mg/kg/day (n = 7). *P < 0.01 compared with control, **P < 0.0001 compared with control therapy groups. The T/C was 0.74 in the TOR 30 group and 0.78 in the LHT group, with a product of 0.58 > 0.53 in the combined therapy groups; and 0.61 in the TOR 120 group and 0.78 in the LHT group, with a product of 0.48 > 0.31 in the combined therapy groups, indicating that the combination therapy had a synergetic effect (Table 1 and Fig. 3 ).
Estrogen Receptor
The mean ER value at the time of tumor resection was 378.0 fmol/mg protein in the control group, which decreased to 203.7, 19.8, and 7.5 fmol/mg protein in the LHT, TOR30, and combined therapy groups, respectively. There were signifi cant differences among the groups. Estrogen receptor expression in the TOR120 group and combined TOR120 + LHT combination group was strongly suppressed and in fact, not detected ( Table 2) .
Analysis of Cell Cycle Kinetics
The analysis of cell cycle kinetics using FCM revealed that the cells in the G0/G1 phase were increased and those in the S phase were decreased in the TOR-alone and combined TOR + LHT groups compared with those in the control and LHT groups. In the combined TOR30 + LHT group, the %S was 23.1% and the %G0/G1 was 71.4%. In the combined TOR120 + LHT group, the %S was 21.7% and the %G0/G1 was 73.6%, indicating a similar tendency. There were signifi cant differences in the %S and %G0/G1 values between the single and combined therapy groups (Table 3) .
Histological Evaluation
Evaluation of the apoptotic index revealed that apoptosis occurred signifi cantly more often in the TOR groups, the LHT group, and the combined TOR + LHT groups than in the control group. There were signifi cant differences in the frequency of apoptosis among the TOR groups, the combined TOR + LHT groups, and the LHT group. On the other hand, the differences between the TOR groups and the combined TOR + LHT groups were not signifi cant (Table 4 and Fig. 4) . Evaluation of the blood vessel density using FVIII RAg revealed that the vascular density in the LHT group was 7.8 and that in the TOR120 group was 8.7, demonstrating decreased vascular density inside the ; open triangles, TOR 30 mg/kg/day (n = 9); closed circles, TOR 120 mg/kg/day (n = 9); closed squares, combination (30 mg/kg/day + LHT) (n = 8); closed triangles, combination (120 mg/kg/day + LHT) (n = 9). *P < 0.05 compared with control and LHT and 30 mg/ kg/day, **P < 0.01 compared with control and LHT and 120 mg/kg/day tumor in these groups compared with that in the control group. However, the vascular density was not decreased around the tumors in the LHT groups. Furthermore, there was a signifi cant decrease in the vascular density at the subdermal and intratumoral areas around or inside the tumors in the combined TOR120 + LHT groups compared with the values in the control and TOR-alone groups (Table 5 and Fig. 5 ). Control (n = 9) 13.5 ± 2.9 10.2 ± 1.1 LHT (n = 9) 11.5 ± 2.3 7.8 ± 0.9 a TOR 30 mg/kg (n = 9) 12.1 ± 1.7 9.3 ± 1.1 TOR 120 mg/kg (n = 9) 12.6 ± 2. 
Intratumoral Concentrations of TOR and its Metabolites, Tore 1 and Tore 2, Inside the Tumors
The concentrations of TOR and its metabolites, Tore 1 and Tore 2, inside the tumors did not differ signifi cantly among the TOR30 or TOR120 alone groups and the combined TOR + LHT groups (Table 6 ).
Discussion
Various endocrine agents have been developed for the treatment of breast cancer. Hyperthermia has also been used, in combination with endocrine therapy, chemotherapy, or radiation therapy, for advanced, recurrent breast cancer. Many reports describe the combined use of HT with chemotherapy or radiotherapy; for example, combined weekly paclitaxel and HT 26 and combined HT + irradiation without invasive thermometry, for the treatment of locally recurrent breast cancer. 27 However, to our knowledge there are no experimental reports on the effects of combined HT and endocrine therapy. In this study, we evaluated the effects of the combined use of the antiestrogen agent, TOR, a safe drug that can be administered at high doses, and LHT, against MCF-7, an estrogen receptor-positive breast cancer cell line. The effects of this treatment on the tumor cells and cell dynamics were evaluated, with histological and pharmacologic examinations.
Toremifene was synthesized as a TAM derivative with a nonsteroidal skeleton at Farmos (Turku, Finland) in 1981. The agent has a low toxicity and can be administered at high doses. Unlike TAM, the longterm use of which has been associated with secondary carcinogenesis, such as endometrial carcinoma, 3, 4 TOR has been shown to have a low incidence of DNA epimorphosis, being 1/136th that associated with TAM. 28 The gene modifi cation rate associated with TOR is also signifi cantly lower than that associated with TAM; 29 therefore, the incidence of secondary carcinogenesis is expected to be lower with TOR. The mechanism of action of TOR is thought to be similar to that of TAM: the drug exerts antiestrogen actions, with their antitumor effects, by competitively inhibiting the binding of 17β-estradiol (E2) to the ER.
1,2 However, at high doses, the drug is also believed to exert antitumor effects via a different mechanism of action. 2, 30 The results of our study showed the dose-dependent antitumor effects of the drug when cancer cells were subjected to TOR alone at 30, 60, 120, and 180 mg/kg/day. The ER expression level in the TOR30 group, treated with the lowest dose of the drug, was signifi cantly decreased to 19.8 fmol/mg protein from that of 378.0 fmol/mg protein in the control group, signifying the association of the antiestrogen actions of the drug with its antitumor effects.
Thermal therapy has been applied clinically for recurrent or inoperable cancers of the breast and other types of cancer. Dewey et al. 31 reported that when HT was used alone on Chinese hamster ovary cells, temperatures of 43°C or higher were necessary to achieve antitumor effects. In our study, 43°C had no antitumor effect but tended to aggravate the tumor, whereas 43.5°C resulted in a remarkable antitumor effect. Kano et al. 32 explained that in HT, protein degeneration occurs when the temperature exceeds 43°C, whereas thermotolerance is induced during heating to temperatures below 43°C. Moreover, the effects of HT are sometimes reversed. For example, Dickson and Hewett, 33 who evaluated the effects of LHT against solid Yoshida sarcoma-transplanted rats, observed marked antitumor effects at 42°C, but tumor growth at 40°C.
In the present study, we evaluated the effects of combined TOR and LHT therapy using a low TOR dose of 30 mg/kg/day (TOR30 + LHT group) and a high TOR dose of 120 mg/kg/day (TOR120 + LHT group). Tumor growth was more suppressed in both the combined therapy groups than in the corresponding TOR-alone groups. The T/C in the combined TOR30 + LHT group was 0.74 × 0.78 = 0.58 > 0.53 and that in the combined TOR120 + LHT combination group was 0.61 × 0.78 = 0.48 > 0.31. Thus, the effect of the treatment modalities in both the combined treatment groups was synergetic. Evaluation of the effects of treatment on ER expression revealed a decrease in the receptor expression in both the TOR30 and TOR120 groups. In the LHT-alone group, the ER expression level was decreased, at 203.7 fmol/mg protein; approximately 54% that in the control group. This suggests that LHT, unlike antiestrogen agents, did not target only ER-positive cells so it may also be effective against ER-negative breast cancers. Kobayashi 34 reported that exposure to LHT at 43°C for 20 min, twice a week for 3 weeks produced remarkable antitumor effects in the ER-negative human strain, MX-1. The ER value in our combined TOR30 + LHT group was signifi cantly lower than that in either the control group or the corresponding TOR-alone groups, suggesting that the treatment modalities in the combined group produced synergetic effects.
Analysis of the cell cycle kinetics using fl ow cytometry (FCM) revealed an increase of cells in the G0/G1 phase and a decrease of cells in the S phase in both the TOR30 and TOR120 groups, compared with the control group. This fi nding is consistent with that of TAM, which also induced an accumulation of cells in the G0/ G1 phase and a decrease of cells in the S phase. 35, 36 After HT, the survival rate of cells was high in the G1 phase and on the border between the G1 and S phases, intermediate between the G2 and M phases, and low in the latter half of the S phase. After radiation therapy, the survival rate of cells was high in the G1 phase and the latter half of the S phase, and low on the border between the G1 and S phases and between the G2 and M phases. Thus, HT and radiation therapy may produce complementary effects, and a combination of the two may be effective. 32 In the present study, there was no difference in cell cycle kinetics between the LHT group and the control group. Walsh et al. 37 reported that heat shock induced a G1 phase delay dependent on the temperature and duration of HT, and Mackey et al. 38, 39 reported that G1 cells, being more heat-resistant than S-phase cells, dominate the asynchronous heat survival response and heat sensitivity decreases as cells progress out of the S phase. These observations probably account for chronic thermotolerance, which could explain why there was no increase in the number of cells in the G1 phase, and possibly minimal thermotolerance or recovery from heat damage at the completion of HT, in the present study. However, there was a signifi cant increase of cells in the G0/G1 phase and decrease of cells in the S phase in both the combined therapy groups (TOR30 + LHT and TOR120 + LHT), compared with the control group or either of the single-treatment groups. This suggests that the antitumor effect of TOR was augmented by the antitumor effect of LHT.
Histologically, TUNEL staining demonstrated apoptosis. Some reports 7, 8 suggested induction of the expression of testosterone-repressed prostatic message-2 (TRPM-2) and tumor growth factor beta-1 (TGF-β1) by TOR. Similarly, apoptosis and TGF-β1 were also induced by TAM in the MCF-7 cell line through its effects on the ER expression, suggesting an association of TGF-β1 with ER expression. 6 FVIII RAg evaluation of vascular density revealed decreased vascular density in the tumors from the highdose TOR120 group, suggesting that TOR suppresses angiogenesis. This fi nding is consistent with reports that antiestrogen agents suppress angiogenesis 9, 10, 40, 41 and the reported suppression of angiogenesis by TOR, both in vitro and in vivo. 42 Haran 10 proposed that the reduced endothelial cell density caused by TAM was a result of its antiestrogenic activity, associated with inhibited production and secretion of angiogenic stimulatory factors. On the other hand, the fi nding of Gagliardi and Collins 9 that the angiostatic activity of estrogen antagonists was not altered in the presence of excess estrogens suggests that the mechanism of this activity is not related to the antiestrogen actions of the drugs. Furthermore, TAM has been reported to decrease the production and release of the extracellular vascular endothelial growth factor (VEGF) in solid MCF-7 tumors. Thus, it was suggested that TAM reduces the extracellular levels of this factor by blocking either the secretion or release of a stored pool of VEGF from the cancer cells. 43 However, the precise mechanism of suppression of angiogenesis by antiestrogen agents remains unclear.
Apoptosis and angiogenesis, as induced by antiestrogen agents, have been pointed out as the mechanisms of action of HT. [13] [14] [15] [16] [17] Harmon et al. 16 reported that in vitro experiments using mastocytoma P-815 cells revealed marked apoptosis at 43°C, 43.5°C, and 44°C, apoptosis and necrosis at 45°C, and necrosis only at 46°C and 47°C. They proposed that apoptosis was induced by the increased cytosolic calcium levels and DNA damage in the cytoplasm resulting from heat on the cell membrane. In the present study, apoptosis was observed in the LHT-alone treatment group, exposed to 43.5°C for 30 min, associated with extensive necrosis at the center of the tumors (data not shown), suggesting that LHT induced apoptosis and affected other factors, such as the in vivo vascular system. Local HT is thought to decrease the vascular density in tumors, which indicates that the suppression of neogenesis of nutritive blood vessels in tumors and the direct damage of blood vessels may be involved in the induction of necrosis. Malignant tumor tissues are considered to be more sensitive to heat than normal tissues, including blood vessels, 13, 14 and are therefore more vulnerable to apoptosis and necrosis. Fajardo and Prionas 17 observed the suppression of angiogenesis by HT, and reported that some of the antineoplastic effects of heat are caused by ischemia resulting from obstruction or destruction of the tumor vessels or inhibition of the formation of new vessels.
One of the clinical factors considered to explain the primary effect of HT was the concurrent use of hormonotherapy. 44 This supports the present experiment, conducted to evaluate the effect of combined therapy with the endocrine agent TOR and HT. TOR alone was effective at 30, 60, 120, and 180 mg/ kg/day, and low-dose TOR at 30 mg/kg/day and highdose TOR at 120 mg/kg/day in combination with LHT exerted synergetic antitumor effects. Histological examination of the tumors revealed more marked apoptosis in the combined therapy groups than in the control or LHT-alone groups. Although an abundance of microvessels at the edge of and within the tumor were clearly associated with conditions that promote tumor growth in the nude mouse animal model using MCF-7, 45 the vascular density in the subcutaneous area of the rim and inside the tumors was signifi cantly decreased in the combined therapy groups compared with that in the control or LHT-alone groups. A remarkable decrease of the vascular density was observed in the combined TOR120 + LHT groups compared with the TOR-alone group, suggesting that the combined synergetic effect of TOR and LHT was caused by the antiangiogenesis effect of the two modalities.
The effect of combined chemotherapy with HT is reportedly augmented in multiplication. Kobayashi 34 evaluated the effects of local thermal chemotherapy using cisplatin against a nude mouse-transplantable human breast cancer cell line. They stated that the principal mechanism of the synergetic action of the combined therapy was assistance of the transmigration of the chemotherapeutic agent into the tumors by heat. In the present study, the concentrations of TOR and its metabolites, Tore 1 and Tore 2, in the tumors were measured in the TOR-alone and combined TOR + LHT groups. We found no differences in concentrations among the groups, suggesting that the antitumor effects of the combined therapy were not attributable to heat assisting the transmigration of TOR into the tissues.
